Dr Sharon Discusses How Insurers Have Responded to the Availability of Therapies for RLS

In this video, Denise Sharon, MD, PhD, Clinical Director and Founding Partner, Comprehensive Sleep Medicine Center of the Gulf Coast, discusses how insurers have responded to the availability of therapies and changes in clinical practice guidelines for RLS.

Related Videos

Related Content

Advertisement

November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

November 18th 2024

KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial

Mary Caffrey

Results bring more competition to treat this genetically driven target for cardiovascular risk.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

November 18th 2024

Cardiomyopathy Risk Plummets When Sacubitril/Valsartan Taken With Chemo

Mary Caffrey

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

November 18th 2024

Benefits of Finerenone Similar in Women and Men, Analysis Finds

Mary Caffrey

Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.

Related Content

Advertisement

November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

November 18th 2024

KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial

Mary Caffrey

Results bring more competition to treat this genetically driven target for cardiovascular risk.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

November 18th 2024

Cardiomyopathy Risk Plummets When Sacubitril/Valsartan Taken With Chemo

Mary Caffrey

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

November 18th 2024

Benefits of Finerenone Similar in Women and Men, Analysis Finds

Mary Caffrey

Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.